Xifeng Lu

Title: Xifeng Lu: Innovator in Pharmaceutical Composition

Introduction

Xifeng Lu is a notable inventor based in Lianyungang, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compositions that enhance drug efficacy and stability. With a total of 2 patents, his work is paving the way for advancements in cancer treatment and other medical applications.

Latest Patents

Xifeng Lu's latest patents include a solid pharmaceutical composition comprising a TLR7 agonist. This composition features 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine, which is noted for its excellent stability and dissolution properties. Another significant patent is for a pharmaceutical composition of a MEK inhibitor, which includes 6-(2-chloro-4-iodophenylamino)-N-(2-hydroxyethoxy)-5-methyl-4-oxo-4,5-dihydrofuro[3,2-c]pyridine-7-carboxamide. This composition can be dispersed in water to form a pharmaceutical suspension with a median particle size, X50, of 0.5 µm to 4.0 µm, and is aimed at treating cancers.

Career Highlights

Xifeng Lu is currently associated with Chia Tai Tianqing Pharmaceutical Group Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work focuses on creating compositions that not only improve drug delivery but also enhance therapeutic outcomes for patients.

Collaborations

Xifeng Lu collaborates with talented individuals such as Min Li and Shang Wang, who contribute to the research and development efforts within the company. Their teamwork fosters an environment of innovation and excellence in pharmaceutical advancements.

Conclusion

Xifeng Lu's contributions to pharmaceutical compositions demonstrate his commitment to improving healthcare through innovation. His patents reflect a deep understanding of drug formulation and its impact on treatment efficacy.